Fancalen (CIBERER)

N/A

Report date: 2023/10/26 16:14:35

Base Information

Drug NameFancalen (CIBERER)
Drug Alias NamePGK-FANCA-WPRElentiviral FANCA-transduced hematopoietic stem cell therapyPGK-FANC A-WPRE
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Lentiviral vector
Mechanisms of ActionFANCA gene transference
TargetsFanconi anemia group A protein
Therapy Area/IndicationsFanconi Anemia
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesCiberer
China Registration ClassN/A

Develop Information

Active CompaniesCentre For Biomedical Network Research On Rare Diseases
Inactive CompaniesN/A
Active IndicationsFanconi Anemia
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A